Survivorship Program Increases Satisfaction, Improves Quality of Life in Recurrent Breast Cancer

October 2nd 2019

“Survivors living with recurrent breast cancer have unique needs and programs that address these needs can enhance patient satisfaction,” the study authors wrote.

Addition of CDK4/6 Inhibitors to Faslodex Improves Survival in Breast Cancer Subgroup

September 30th 2019

Two studies showed that adding a CDK4/6 inhibitor to treatment with Faslodex improved survival among women with hormone receptor-positive, human epidermal growth factor2-negative advanced breast cancer.

Frontline Tagrisso Improves Survival Among Specific Subgroup of Patients with NSCLC

September 30th 2019

First-line Tagrisso significantly extended overall survival compared with first generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer, according to results from the phase 3 FLAURA study.

Opdivo-Yervoy Combination Induces Long-Term Survival in Metastatic Melanoma

September 29th 2019

One in two patients with metastatic melanoma is alive five years following treatment with Opdivo plus Yervoy, according to long-term follow-up of the phase 3 CheckMate 067 trial.

Frontline Zejula Maintenance Therapy Improves Survival in Advanced Ovarian Cancer

September 29th 2019

Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.

Frontline Opdivo, Yervoy May Improve Survival in Non-Small Cell Lung Cancer

September 29th 2019

First-line treatment with Opdivo plus low-dose Yervoy improved survival among patients with advanced NSCLC compared to chemotherapy, according to results from the CheckMate-227 trial.

Addition of PARP Inhibitor to Maintenance Therapy May Improve Survival in Ovarian Cancer

September 28th 2019

The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.

Erleada May Extend Subsequent Progression in Men With Castration-Resistant Prostate Cancer

September 28th 2019

Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.